- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The Board of Starpharma Holdings Limited (Starpharma or Company) advises that the Company has today settled the placement of 30,000,000 ordinary shares at a share price of A$0.52 (Shares) in the Company, to institutional, sophisticated and professional investors, as announced on 18 November 2009.
The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Corporations Act). Starpharma provides this notice in accordance with section 708A(5)(e) of the Corporations Act.
Starpharma notifies ASX (as operator of the prescribed financial market on which the ordinary shares are or are to be quoted) that, as at the date of this notice, Starpharma has complied with the provisions of Chapter 2M of the Corporations Act (as they apply to Starpharma), and with section 674 of the Corporations Act.
As at the date of this notice, Starpharma is not in possession of any excluded information within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.
About Starpharma Holdings Limited
Starpharma Holdings Limited is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications.
Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.
For more information, please click here
Licensing and Partnerships
M: +61 417 382 391
T: +61 2 9237 2800
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015